La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Kaken Pharmaceutical Croissance future

Future contrôle des critères 0/6

Informations clés

-43.7%

Taux de croissance des bénéfices

-43.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	13.9%
Taux de croissance des recettes	-5.5%
Rendement futur des capitaux propres	0.3%
Couverture par les analystes	Low
Dernière mise à jour	11 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

TSE:4521 - Estimations futures des analystes et données financières antérieures (JPY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	60,300	440	603	4,703	1
3/31/2026	65,900	2,710	5,103	9,203	1
3/31/2025	83,100	13,400	12,418	14,518	1
3/31/2024	72,044	8,025	410	2,577	N/A
12/31/2023	72,096	2,966	N/A	N/A	N/A
9/30/2023	72,336	3,544	714	2,581	N/A
6/30/2023	72,937	5,043	N/A	N/A	N/A
3/31/2023	72,984	5,440	7,047	9,253	N/A
12/31/2022	73,899	8,452	N/A	N/A	N/A
9/30/2022	75,265	8,792	11,478	14,329	N/A
6/30/2022	75,778	9,094	N/A	N/A	N/A
3/31/2022	76,034	9,549	10,079	13,336	N/A
12/31/2021	75,605	12,717	N/A	N/A	N/A
9/30/2021	75,778	12,900	10,134	13,123	N/A
6/30/2021	75,362	12,947	N/A	N/A	N/A
3/31/2021	74,979	13,405	12,094	14,380	N/A
12/31/2020	76,136	14,750	N/A	N/A	N/A
9/30/2020	80,851	17,049	16,658	18,502	N/A
6/30/2020	84,967	18,364	N/A	N/A	N/A
3/31/2020	89,232	19,370	25,266	27,468	N/A
12/31/2019	91,759	19,082	N/A	N/A	N/A
9/30/2019	91,814	18,482	27,065	29,746	N/A
6/30/2019	92,365	18,566	N/A	N/A	N/A
3/31/2019	94,165	17,775	19,001	21,129	N/A
12/31/2018	94,123	16,431	N/A	N/A	N/A
9/30/2018	96,091	17,015	15,607	17,657	N/A
6/30/2018	97,598	17,615	N/A	N/A	N/A
3/31/2018	98,430	19,043	19,815	21,703	N/A
12/31/2017	99,405	20,893	N/A	N/A	N/A
9/30/2017	99,160	21,439	N/A	20,714	N/A
6/30/2017	100,218	21,684	N/A	N/A	N/A
3/31/2017	101,479	22,017	N/A	15,327	N/A
12/31/2016	103,264	18,992	N/A	N/A	N/A
9/30/2016	106,936	20,106	N/A	22,215	N/A
6/30/2016	108,325	20,639	N/A	N/A	N/A
3/31/2016	109,730	21,143	N/A	27,067	N/A
12/31/2015	108,165	22,651	N/A	N/A	N/A
9/30/2015	104,630	18,966	N/A	22,113	N/A
6/30/2015	100,058	15,792	N/A	N/A	N/A
3/31/2015	93,889	12,122	N/A	14,737	N/A
12/31/2014	93,083	11,909	N/A	N/A	N/A
9/30/2014	89,466	10,776	N/A	10,586	N/A
6/30/2014	89,140	10,158	N/A	N/A	N/A
3/31/2014	88,946	9,735	N/A	13,663	N/A
12/31/2013	87,267	9,042	N/A	N/A	N/A
9/30/2013	87,243	8,973	N/A	12,340	N/A

Kaken Pharmaceutical Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 18%

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024

Consensus EPS estimates fall by 26%, revenue upgraded

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Price target lowered to JP¥3,800

Recent updates

Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Consensus revenue estimates increase by 18%

Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00

Now 20% overvalued after recent price rise

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024

Third quarter 2024 earnings released: EPS: JP¥68.84 (vs JP¥85.00 in 3Q 2023)

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings released: EPS: JP¥41.28 (vs JP¥81.46 in 2Q 2023)

Upcoming dividend of JP¥75.00 per share at 4.2% yield

Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)

Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023

Kaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024

First quarter 2024 earnings released: EPS: JP¥66.98 (vs JP¥76.89 in 1Q 2023)

New minor risk - Dividend sustainability

Consensus EPS estimates fall by 26%, revenue upgraded

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥75.00 per share at 4.1% yield

Third quarter 2023 earnings released: EPS: JP¥84.99 (vs JP¥93.21 in 3Q 2022)

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

First quarter 2023 earnings released: EPS: JP¥76.89 (vs JP¥87.76 in 1Q 2022)

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 03, 2022

Kaken Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 30, 2022; Provides Second Quarter and Fiscal Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 350,000 shares, representing 0.92% for ¥1,500 million.

Less than half of directors are independent

Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of ARTham Therapeutics Inc for ¥5.5 billion.

Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire ARTham Therapeutics Inc.

Second quarter 2022 earnings released: EPS JP¥88.47 (vs JP¥87.95 in 2Q 2021)

Upcoming dividend of JP¥75.00 per share

First quarter 2022 earnings released: EPS JP¥87.76 (vs JP¥98.16 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥347 (vs JP¥495 in FY 2020)

Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 500,000 shares, representing 1.3% for ¥2,500 million.

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 07, 2021

New 90-day high: JP¥4,220

Third quarter 2021 earnings released: EPS JP¥96.58 (vs JP¥154 in 3Q 2020)

New 90-day low: JP¥3,805

Price target lowered to JP¥3,800

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 03, 2021

Brickell Biotech, Inc. Announces Launch Date for Sofpironium Bromide Gel in Japan by Kaken Pharmaceutical Co., Ltd

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 05, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance